Intellia Therapeutics, Inc. (NTLA) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR-based gene editing therapies. The company's lead candidates are lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis. In April 2026, the company reported positive topline data from the Phase 3 HAELO trial for lonvo-z and initiated a rolling Biologics License Application (BLA) with the FDA.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Collaboration Revenue | $22,707 |
| Net Loss | $(202,865) |
| Net Loss Per Share (Basic & Diluted) | $(1.61) |
| Research & Development Expenses | $163,332 |
| General & Administrative Expenses | $72,667 |
| Cash, Cash Equivalents, and Marketable Securities | $628,400 |
| Net Cash Used in Operating Activities | $(200,459) |
| Net Cash Provided by Financing Activities | $229,685 |
Material Changes vs. Prior Period
- Revenue: Collaboration revenue decreased by $8.2 million (26%) compared to the six months ended June 30, 2025, primarily due to reduced revenue under the Regeneron agreements and the absence of a hemophilia B milestone payment recognized in the prior year.
- Expenses: Total operating expenses decreased by $25.7 million. R&D expenses dropped $42.1 million (21%) driven by lower external development costs for nex-z and lonvo-z, reduced stock-based compensation, and lower research material costs. G&A expenses increased $16.5 million due to legal fees and commercial infrastructure buildout.
- Net Loss: Net loss improved by $12.7 million to $202.9 million, reflecting the significant reduction in operating expenses.
- Capital Raise: In April 2026, the company completed a follow-on public offering raising $194.6 million in net proceeds. Additionally, $33.6 million was raised through at-the-market offerings during the period.
Outlook, Risks, and Management Commentary
- Lonvo-z (HAE): Following positive Phase 3 data showing an 87% reduction in attacks, the company expects FDA acceptance of the BLA in the second half of 2026, with a planned commercial launch in the first half of 2027.
- Nex-z (ATTR): The FDA lifted clinical holds on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials in Q1 2026 following a safety review. Enrollment is advancing, with completion expected in the second half of 2026. The company identified a specific HLA allele associated with liver transaminase elevations and is implementing genotyping for trial participants.
- Liquidity: Management expects current cash, cash equivalents, and marketable securities ($628.4 million) combined with collaboration funding to fund operations through at least 2028.
- Real Estate: The company entered a new 12-year lease at 400 Technology Square in Cambridge, with rent commencing in December 2026. Prepaid rent of $51.4 million was recorded as of June 30, 2026.
- Legal Proceedings: A securities class action lawsuit (Gonzalez v. Intellia) was dismissed with prejudice in June 2026. Patent litigation with BlueAllele Corp. remains ongoing with discovery in progress.
Investor Verification Checklist
- Verify the timeline for FDA acceptance of the lonvo-z BLA and the specific criteria for the planned H1 2027 launch.
- Monitor the enrollment progress and safety data of the nex-z Phase 3 trials (MAGNITUDE/MAGNITUDE-2) post-clinical hold lift.
- Review the impact of the new 400 Technology Square lease on future cash flow and operating expenses starting late 2026.
- Assess the status of the BlueAllele Corp. patent infringement litigation and potential financial exposure.
- Confirm the sustainability of collaboration revenue streams with Regeneron as milestone payments fluctuate.